[Endophthalmitis following cataract surgery].
BACKGROUND
Infectious endophthalmitis is a serious complication following cataract surgery, since it often induces a substantial reduction of visual acuity.


METHODS
We retrospectively evaluated the clinical data of 53 patients with endophthalmitis following cataract surgery who were treated at the department of ophthalmology of the University Hospital in Ulm between 1995 and May 2001. Of these patients, 50 had been referred. Clinical presentation, infecting organism, treatment and visual outcome were analysed with a followup ranging from 2 weeks up to 42 months (median: 6 months).


RESULTS
In 52 patients endophthalmitis was preceeded by cataract extraction and IOL implantation, in one case by secondary IOL implantation. Confirmed microbiologic growth was demonstrated from intraocular specimens in 26 out of 41 operated eyes (63%), the most frequent causative organisms were coagulase-negative Staphylococci (50%). All isolated bacteria were sensitive to a combination of the antibiotics vancomycin and amikacin or vancomycin and ceftazidime. 13 patients were treated with intravenous antibiotic therapy alone. In 46% of patients, who were initially treated with intraocular antibiotic injections alone, required further therapeutic intervention for recurrent infection. Only 7.7% of the patients who initially underwent intraocular antibiotic injections combined with IOL removal or pars plana vitrectomy with or without IOL removal, required further surgical intervention. Initial visual acuity was hand movements (median) only but improved during follow-up to 0.2 (median).


CONCLUSIONS
In this series all tested bacteria were susceptible to the combination of vancomycin with either amikacin or ceftazidime. Aggressive initial treatment including IOL removal may be associated with a lower frequency of recurrent disease.
Hesse
Y
Y
Universitätsaugenklinik Ulm.
Spraul
C W
CW
Lang
G K
GK
D000583:Amikacin / Q000008:administration & dosage; D002439:Cefotaxime / Q000008:administration & dosage; D002442:Ceftazidime / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D009877:Endophthalmitis / Q000209:etiology / Q000601:surgery*; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007910:Lenses, Intraocular; D011183:Postoperative Complications / Q000209:etiology / Q000601:surgery*; D016459:Prosthesis-Related Infections / Q000209:etiology / Q000601:surgery*; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000209:etiology / Q000601:surgery*; D014640:Vancomycin / Q000008:administration & dosage; D014792:Visual Acuity; D014821:Vitrectomy
D014640:Vancomycin; D000583:Amikacin; D002442:Ceftazidime; D002439:Cefotaxime